The drug under scrutiny is $lamotrigine$, and the task is to match it with its most characteristic toxicity rather than confuse it with the side-effect profile of other antiepileptics.
Lamotrigine's defining hazard is dermatological. A skin $rash$ develops in a noticeable fraction of patients and can escalate to the severe end of the spectrum - $Stevens$-$Johnson$ syndrome and toxic epidermal necrolysis. Two situations sharply increase this danger: starting at too high a dose or escalating too quickly, and combining the drug with $valproate$, which slows lamotrigine clearance and raises its blood level. For these reasons the drug is introduced with deliberately slow titration. Separately, dose-dependent central effects such as $dizziness$, diplopia and ataxia are frequently reported, which matches the alternative half of the option.
The distractors each belong to a different agent: dose-independent serious $hepatotoxicity$ is a valproate/felbamate problem, $gingival$ overgrowth flags phenytoin, and permanent visual-field loss is the trademark of $vigabatrin$. Assigning any of these to lamotrigine would be an error.
\[\boxed{\text{Lamotrigine} \to \text{rash / SJS-TEN (and dizziness)}}\]